Advertisement

High Blood Pressure & Cardiovascular Prevention

, Volume 26, Issue 5, pp 413–420 | Cite as

Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery

  • Dmitry Sychev
  • Radik MinnigulovEmail author
  • Pavel Bochkov
  • Kristina Ryzhikova
  • Irina Yudina
  • Aleksey Lychagin
  • Tatyana Morozova
Original article
  • 40 Downloads

Abstract

Introduction

Population ageing in developed countries will inevitably increase the need for knee and hip replacement surgery. Over the years, direct oral anticoagulants, such as rivaroxaban, have been widely used for thromboprophylaxis in patients undergoing knee and hip replacement surgery. The study of pharmacogenetic characteristics of rivaroxaban is important for enhancing the effectiveness and safety of rivaroxaban thromboprophylaxis.

Aim

Evaluation of CYP3A4, CYP3A5 and ABCB1 gene polymorphisms influence on rivaroxaban pharmacokinetics and prothrombin time dynamics in patients undergoing total hip and knee replacement surgery.

Methods

The study included 78 patients undergoing total hip and knee replacement surgery. The patients received 10 mg of rivaroxaban once a day. Genotyping of polymorphisms ABCB1 rs1045642, ABCB1 rs4148738, CYP3A4 rs35599367 and CYP3A5 rs776746 was performed. Peak steady-state and trough steady-state rivaroxaban concentrations were determined. Prothrombin time was also evaluated.

Results

The study revealed the following haplotypes: (1) ABCB1 rs1045642—CYP3A4 rs35599367 and (2) ABCB1 rs4148738—CYP3A4 rs35599367. The analysis of the peak steady-state rivaroxaban concentration between mutant haplotypes and wild haplotypes revealed no significant differences. However, there was a statistically significant average correlation between peak steady-state rivaroxaban concentration and prothrombin time (r = 0.421; r2 = 0.178; p < 0.001).

Conclusion

No significant difference was identified in peak steady-state rivaroxaban concentration between mutant haplotypes and wild haplotypes. The revealed statistically significant average correlation between the prothrombin time and peak steady-state rivaroxaban concentration is important in clinical practice for assessing the anticoagulant activity of rivaroxaban.

Keywords

Rivaroxaban Pharmacogenetics Gene polymorphisms Drug concentration P-glycoprotein Thromboprophylaxis 

Notes

Acknowledgements

This study was supported by Russian Science Foundation, project 16-15-00227 “Conducting fundamental scientific research and exploratory research on priority thematic research areas”. We would also like to thank all who participated in this study from Sechenov University’s Clinic of Traumatology, Orthopaedics and Joint Pathology, Department of Clinical Pharmacology and Propedeutics of Internal Diseases of Sechenov University and the R&D Center of Russian Medical Academy for Continuous Professional Education under the Ministry of Health of Russia.

Compliance with Ethical Standards

Conflict of interest

The authors have declared no conflict of interest.

References

  1. 1.
    Waddell J, Johnson K, Hein W, Raabe J, FitzGerald G, Turibio F. Orthopaedic practice in total hip arthroplasty and total knee arthroplasty: results from the Global Orthopaedic Registry (GLORY). Am J Orthop (Belle Mead, NJ). 2010;39:5–13.PubMedGoogle Scholar
  2. 2.
    Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. JBJS. LWW. 2007;89:780–5.Google Scholar
  3. 3.
    Geerts WH, et al. Prevention of venous thromboembolism. Chest. 2001;119:132S–75S.CrossRefGoogle Scholar
  4. 4.
    Agnelli G. Prevention of venous thromboembolism in surgical patients. Circulation. 2004;110:4.  https://doi.org/10.1161/01.CIR.0000150639.98514.6c.CrossRefGoogle Scholar
  5. 5.
    Press Release of Johnson & Johnson. FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery [Internet]. 2011 [cited 2019 Jun 13]. https://www.jnj.com/media-center/press-releases/fda-approves-xarelto-rivaroxaban-tablets-to-help-prevent-deep-vein-thrombosis-in-patients-undergoing-knee-or-hip-replacement-surgery.
  6. 6.
    European Medicines Agency. CHMP assessment report for Xarelto [Internet]. 2008 [cited 2019 Jun 13]. https://www.ema.europa.eu/en/documents/assessment-report/xarelto-epar-public-assessment-report_en.pdf.
  7. 7.
    Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug metabolism and disposition. ASPET. 2009;37:1056–64.Google Scholar
  8. 8.
    Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. British journal of clinical pharmacology. Wiley Online Library; 2013;76:455–66.Google Scholar
  9. 9.
    Online Encyclopedia for Genetic Epidemiology studies. Hardy-Weinberg equilibrium calculator [Internet]. 2008 [cited 2019 Jun 14]. http://www.oege.org/software/hwe-mr-calc.shtml.
  10. 10.
    Scitable by Nature Education: online educational resource for undergraduate biology students and educators. Haplotype / haplotypes [Internet]. [cited 2019 Aug 9]. https://www.nature.com/scitable/definition/haplotype-haplotypes-142/.
  11. 11.
    Gouin-Thibault I, Delavenne X, Blanchard A, Siguret V, Salem JE, Narjoz C, et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB 1 genetic polymorphisms and interaction with clarithromycin. Journal of Thrombosis and Haemostasis. Wiley Online Library; 2017;15:273–83.Google Scholar
  12. 12.
    Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemostasis. 2008;100:453–61.CrossRefGoogle Scholar
  13. 13.
    Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban—an oral, direct factor Xa inhibitor—in patients undergoing major orthopaedic surgery. Clin Pharmacokinet. 2008;47:203–16.CrossRefGoogle Scholar

Copyright information

© Italian Society of Hypertension 2019

Authors and Affiliations

  • Dmitry Sychev
    • 1
  • Radik Minnigulov
    • 2
    Email author
  • Pavel Bochkov
    • 3
  • Kristina Ryzhikova
    • 4
  • Irina Yudina
    • 2
  • Aleksey Lychagin
    • 5
  • Tatyana Morozova
    • 6
  1. 1.Clinical Pharmacology and TherapyRussian Medical Academy of Continuous Professional EducationMoscowRussian Federation
  2. 2.Department of Clinical Pharmacology and Propaedeutics of Internal DiseasesI.M. Sechenov First Moscow State Medical University (Sechenov University)MoscowRussian Federation
  3. 3.Personalized Medicine Department, Research CenterRussian Medical Academy of Continuous Professional EducationMoscowRussian Federation
  4. 4.Department of Molecular Biological Research, Research CenterRussian Medical Academy of Continuous Professional EducationMoscowRussian Federation
  5. 5.Department of Traumatology, Orthopedics and Disaster SurgeryI.M. Sechenov First Moscow State Medical University (Sechenov University)MoscowRussian Federation
  6. 6.Department of General Medical PracticeI.M. Sechenov First Moscow State Medical University (Sechenov University)MoscowRussian Federation

Personalised recommendations